Anticuerpos contra el SARS-CoV-2 tras la dosis de vacuna de recuerdo. Identificación de subgrupos con respuesta insuficiente / SARS-CoV-2 antibodies after booster vaccination. Identification of subgroups with poor response

Objetivo Identificar dentro del grupo de pacientes de alto riesgo a aquellos que presentan más posibilidad de presentar inmunidad postvacunal insuficiente. Método Determinación de títulos de IgG frente a SARS-CoV-2 después de la dosis de recuerdo. Se clasificó la respuesta vacunal como negativa (títulos IgG <34 BAU/ml), indeterminada (títulos 34 - 259 BAU/ml) o positiva (≥260 BAU/ml). Resultados Se incluyeron 765 pacientes (31,25% de los vacunados): 54 (7,1%) en tratamiento con fármacos biológicos, 90 (11,8%) con enfermedad hematológica, 299 (39,1%) con patología oncológica, 304 (39,7%) con trasplante de órgano sólido y 18 (2,4%) con inmunosupresión por otros motivos. Un total de 74 pacientes (9,7%) tuvieron una serología negativa y 45 (5,9%) obtuvieron títulos indeterminados. Por grupo diagnóstico, los pacientes con mayor porcentaje de serología negativa o indeterminada fueron pacientes bajo tratamiento con fármacos biológicos (55,6%, fundamentalmente a expensas de antiCD20), hematológicos (35,4%) y los trasplantados (17,8%, principalmente pulmón y riñón). Los pacientes oncológicos y otros pacientes inmunosuprimidos tuvieron buena respuesta vacunal. Conclusión Los pacientes tratados con fármacos antiCD20, los hematológicos y los trasplantados (fundamentalmente de pulmón y riñón) presentaron mayor riesgo de no desarrollar inmunidad postvacunal. Es fundamental su identificación de cara a individualizar y mejorar su manejo (AU)

Objective To determine which patients within the high-risk group are most likely to have insufficient post-vaccination immunity. Methods Determination of IgG titers against SARS-CoV-2 after the booster dose. Vaccine response was categorized as negative (IgG titers <34 BAU/ml), indeterminate (titers 34 - 259 BAU/ml) or positive (≥ 260 BAU/ml). Results 765 patients were included (31.25% of those vaccinated). 54 (7.1%) on treatment with biologics, 90 (11.8%) with hematologic disease, 299 (39.1%) with oncologic pathology, 304 (39.7%) with solid organ transplant and 18 (2.4%) with immunosuppression for other reasons. 74 patients (9.7%) had negative serology and 45 (5.9%) had indeterminate titers. By diagnostic group, the patients with the highest proportion of negative or indeterminate serology were patients with biologic treatment (55.6%, mainly at expense of antiCD20), hematologic (35.4%) and transplant patients (17.8%, mainly lung and kidney). Oncology and other immunosuppressed patients had a favorable response to vaccination. Conclusion Patients treated with antiCD20 drugs, hematologic patients and transplanted patients (mainly lung and kidney) have a higher risk of not achieving post-vaccination immunity. It is essential to identify them in order to individualize and optimize their management (AU)

[SARS-CoV-2 antibodies after booster vaccination. Identification of subgroups with poor response]. / Anticuerpos contra el SARS-CoV-2 tras la dosis de vacuna de recuerdo. Identificación de subgrupos con respuesta insuficiente.

Objective: To determine which patients within the high-risk group are most likely to have insufficient post-vaccination immunity. Methods: Determination of IgG titers against SARS-CoV-2 after the booster dose. Vaccine response was categorized as negative (IgG titers < 34 BAU/ml), indeterminate (titers 34 - 259 BAU/ml) or positive (≥ 260 BAU/ml). Results: 765 patients were included (31.25% of those vaccinated). 54 (7.1%) on treatment with biologics, 90 (11.8%) with hematologic disease, 299 (39.1%) with oncologic pathology, 304 (39.7%) with solid organ transplant and 18 (2.4%) with immunosuppression for other reasons. 74 patients (9.7%) had negative serology and 45 (5.9%) had indeterminate titers. By diagnostic group, the patients with the highest proportion of negative or indeterminate serology were patients with biologic treatment (55.6%, mainly at expense of antiCD20), hematologic (35.4%) and transplant patients (17.8%, mainly lung and kidney). Oncology and other immunosuppressed patients had a favorable response to vaccination. Conclusion: Patients treated with antiCD20 drugs, hematologic patients and transplanted patients (mainly lung and kidney) have a higher risk of not achieving post-vaccination immunity. It is essential to identify them in order to individualize and optimize their management.

SARS-COV-2 antibodies after booster vaccination. Identification of subgroups with poor response.

OBJECTIVE: To determine which patients within the high-risk group are most likely to have insufficient post-vaccination immunity. METHODS: Determination of IgG titers against SARS-CoV-2 after the booster dose. Vaccine response was categorized as negative (IgG titers < 34 BAU/ml), indeterminate (titers 34-259 BAU/ml) or positive (≥260 BAU/ml). RESULTS: 765 patients were included (31.25% of those vaccinated). 54 (7.1%) on treatment with biologics, 90 (11.8%) with hematologic disease, 299 (39.1%) with oncologic pathology, 304 (39.7%) with solid organ transplant and 18 (2.4%) with immunosuppression for other reasons. 74 patients (9.7%) had negative serology and 45 (5.9%) had indeterminate titers. By diagnostic group, the patients with the highest proportion of negative or indeterminate serology were patients with biologic treatment (55.6%, mainly at expense of antiCD20), hematologic (35.4%) and transplant patients (17.8%, mainly lung and kidney). Oncology and other immunosuppressed patients had a favorable response to vaccination. CONCLUSION: Patients treated with antiCD20 drugs, hematologic patients and transplanted patients (mainly lung and kidney) have a higher risk of not achieving post-vaccination immunity. It is essential to identify them in order to individualize and optimize their management.